Related Experiment Video
Updated: Jul 6, 2025

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Nitric oxide as a double-edged sword in pulmonary viral infections: Mechanistic insights and potential therapeutic
Mohammad Masood1, Prithvi Singh2, Daaniyaal Hariss3
1Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi 110025, India.
Abstract:
In the face of the global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), researchers are tirelessly exploring novel therapeutic approaches to combat coronavirus disease 2019 (COVID-19) and its associated complications. Nitric oxide (NO) has appeared as a multifaceted signaling mediator with diverse and often contrasting biological activities. Its intricate biochemistry renders it a crucial regulator of cardiovascular and pulmonary functions, immunity, and neurotransmission. Perturbations in NO production, whether excessive or insufficient, contribute to the pathogenesis of various diseases, encompassing cardiovascular disease, pulmonary hypertension, asthma, diabetes, and cancer. Recent investigations have unveiled the potential of NO donors to impede SARS-CoV- 2 replication, while inhaled NO demonstrates promise as a therapeutic avenue for improving oxygenation in COVID-19-related hypoxic pulmonary conditions. Interestingly, NO's association with the inflammatory response in asthma suggests a potential protective role against SARS-CoV-2 infection. Furthermore, compelling evidence indicates the benefits of inhaled NO in optimizing ventilation-perfusion ratios and mitigating the need for mechanical ventilation in COVID-19 patients. In this review, we delve into the molecular targets of NO, its utility as a diagnostic marker, the mechanisms underlying its action in COVID-19, and the potential of inhaled NO as a therapeutic intervention against viral infections. The topmost significant pathway, gene ontology (GO)-biological process (BP), GO-molecular function (MF) and GO-cellular compartment (CC) terms associated with Nitric Oxide Synthase (NOS)1, NOS2, NOS3 were arginine biosynthesis (p-value = 1.15 x 10-9) regulation of guanylate cyclase activity (p-value = 7.5 x 10-12), arginine binding (p-value = 2.62 x 10-11), vesicle membrane (p-value = 3.93 x 10-8). Transcriptomics analysis further validates the significant presence of NOS1, NOS2, NOS3 in independent COVID-19 and pulmonary hypertension cohorts with respect to controls. This review investigates NO's molecular targets, diagnostic potentials, and therapeutic role in COVID-19, employing bioinformatics to identify key pathways and NOS isoforms' significance.
Insights
Nitric oxide (NO) shows potential in treating COVID-19 by inhibiting SARS-CoV-2 replication and improving oxygenation. Inhaled NO may reduce mechanical ventilation needs in patients with coronavirus disease 2019.
Area of Science:
- Biochemistry and Molecular Biology
- Immunology
- Pulmonology
Background:
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19, necessitating novel therapeutic strategies.
- Nitric oxide (NO) is a signaling molecule with critical roles in cardiovascular and pulmonary functions, immunity, and neurotransmission.
- Dysregulation of NO production is implicated in various diseases, including cardiovascular disease, pulmonary hypertension, and asthma.
Purpose of the Study:
- To review the molecular targets, diagnostic potential, and therapeutic applications of nitric oxide (NO) in COVID-19.
- To explore the mechanisms of NO action in COVID-19 pathogenesis and its potential as an inhaled therapy.
- To identify key pathways and the significance of Nitric Oxide Synthase (NOS) isoforms in COVID-19 using bioinformatics.
Main Methods:
- Literature review focusing on NO donors, inhaled NO, and NO's role in inflammation and asthma.
- Bioinformatic analysis of gene ontology terms (biological process, molecular function, cellular compartment) for NOS1, NOS2, and NOS3.
- Transcriptomics analysis comparing COVID-19 and pulmonary hypertension cohorts with controls to assess NOS isoform expression.
Main Results:
- NO donors may inhibit SARS-CoV-2 replication; inhaled NO shows promise for improving oxygenation in COVID-19 patients.
- NO is associated with regulating guanylate cyclase activity, arginine binding, and is localized to vesicle membranes.
- Transcriptomics analysis confirmed significant expression of NOS1, NOS2, and NOS3 in COVID-19 and pulmonary hypertension cohorts.
Conclusions:
- Nitric oxide (NO) presents a promising therapeutic avenue for COVID-19, potentially by inhibiting viral replication and improving pulmonary function.
- Inhaled NO may optimize ventilation-perfusion ratios and reduce the need for mechanical ventilation in COVID-19 patients.
- Further research into NO's molecular targets and NOS isoforms is crucial for developing effective COVID-19 treatments.
More Related Videos
08:23Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Related Concept Videos
Nitric Oxide Signaling Pathway
Pneumonia II: Pathophysiology
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antihypertensive Drugs: Vasodilators